Veozah
(Fezolinetant)ApprovedSmall molecule
AstellasFezolinetant is used to treat moderate to severe hot flashes and night sweats that occur during menopause in women.[2] Veozah is currently approved and in use across 5 indications[4].[1]
Veozah is one of 155 small molecule programs targeting Kidney Disease. It is currently in Approved.
5
Indications
26
Total Trials
8
Active Trials
154
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPhase 3
Cabometyx
Bristol-Myers SquibbPhase 3
Veozah
AstellasApproved
Zejula
GGlaxo Dba Glaxosmithkline
Phase 3
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Antiandrogen Therapy
UUniversity of Washington
Phase 3
Lutetium Lu-177 PNT2002
JJonsson Comprehensive Cancer Center
Phase 3
Rhpsma-7.3 (18f)
BBlue Earth Diagnostics
Phase 3
HC-1119
HHinova Pharmaceuticals Inc.
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hot flashes15 trials
Show 12 more trials
Female3 trials
Menopause2 trials
Breast Cancer2 trials
Regulatory
FDA Approval Timeline[5]
May 12, 2023
VEOZAH
NDA NDA216578
May 12, 2023
VEOZAH
NDA NDA216578
Aug 31, 2024
VEOZAH
NDA NDA216578
Dec 16, 2024
VEOZAH
NDA NDA216578
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Veozah drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Fezolinetant. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Veozah. U.S. Food & Drug Administration.
- [7]